We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Marvin D. Jones
Marvin D. Jones
Products
PRODUCTS
Crown Laboratories Inc./dba Del-Ray Dermatologicals
Zada L. Giles
and
Marvin D. Jones
Price:
$117.00
View
Dr. Reddy’s Laboratories Louisiana, LLC
Samantha J. Bradley
,
Samuel L. Collins
, and
Marvin D. Jones
Price:
$117.00
View
Cardinal Health 414, LLC
Samantha J. Bradley
and
Marvin D. Jones
Price:
$117.00
View
Baxter Healthcare Corp.
Samantha J. Bradley
and
Marvin D. Jones
Price:
$117.00
View
Chattem Chemicals, Inc.
Zada L. Giles
,
Brandon C. Heitmeier
, and
Marvin D. Jones
Price:
$117.00
View
PharMEDium Services, LLC
Marvin D. Jones
Price:
$117.00
View
PharMEDium Services, LLC
Marvin D. Jones
Price:
$117.00
View
Central Admixture Pharmacy Services, Inc.
Marvin D. Jones
,
Stanley M. Shepperson
, and
Cheryl L. Watson
Price:
$117.00
View
Delta Pharma, Inc.
Wayne S. Fortenberry
and
Marvin D. Jones
Price:
$117.00
View
AL&S, LLC
Zada L. Giles
and
Marvin D. Jones
Price:
$117.00
View
View All Products by Marvin D. Jones
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More